Latest Headlines

  1. Optimi Health Secures Ibogaine Supply And Commences Finished Drug Product Development 6/8/2026

    Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today provided an update on its recently announced Ibogaine Initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form.

  2. Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi 6/5/2026

    Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist.

  3. DaltonTx Launches Its Drug Discovery Platform, Dalton, And Announces Sygnature Discovery Collaboration 6/4/2026

    DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, today announced the launch of Dalton, its drug discovery platform.

  4. Chai Discovery Announces License Agreement With Pfizer To Accelerate Drug Discovery With AI 6/4/2026

    Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.

  5. Terremoto Biosciences Granted FDA Fast Track Designation For TER-2013, An AKT1-Selective Small Molecule Inhibitor For Breast Cancer 6/3/2026

    Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TER-2013, the Company’s lead AKT1-selective inhibitor, in patients with locally advanced, unresectable or metastatic HR+/HER2- breast cancer harboring one or more AKT/PI3K/PTEN alterations following progression on at least one endocrine-based therapy and CDK4/6 inhibitor for advanced disease.

  6. Ingenix Raises €13M From Sofinnova Partners-Led Syndicate To Scale Modality Fusion, A Novel Architecture For Drug Development 6/3/2026

    Ingenix, the AI and biology company built around a single question - "What would it take for AI to truly understand biology?" - has today announced a €13m seed-extension funding round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.

  7. Persist AI Teams Up With Microsize And Micromacinazione (Micmac) To Launch First-Of-Its-Kind Early-Stage 'Micromill' Formulation Platform, Enabling Drug Development Decision With Milligrams Of API 6/3/2026

    Persist AI, an AI and robotics-powered pharmaceutical formulation research company, today announced a strategic collaboration with Microsize and Micromacinazione, pioneers in pharmaceutical micronization with over 30 years of industry experience. Together, the three companies have built the world's first integrated platform capable of determining oral formulation strategy with milligrams of API.

  8. Genomics Launches The Mystra AI Platform, Adopted By Industry Giants And Up-And-Coming Biotechs 6/2/2026

    Genomics, a science-led Techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has today announced the launch of Mystra AI, the best-in-class human genetics agentic AI platform designed to supercharge drug target discovery and validation.

  9. Launch Of TechBio Firm, Lucera, Brings Decision Intelligence To Drug Development, Making It More Predictable, More Evidence-Grounded, And More Efficient 6/2/2026

    Lucera GmbH, a TechBio company utilizing its proprietary technology to transform pharmaceutical R&D and enhance development efficacy and efficiency through unique decision intelligence, today announced the launch of its operations.

  10. Sanofi Chooses Snowflake To Accelerate Its AI-Powered Drug Development 6/2/2026

    SNOWFLAKE SUMMIT 26 – Snowflake, the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit.